CH-5447240, also known by its CAS number 1253919-92-4, is a chemical compound that has garnered attention in pharmaceutical research, particularly in the context of its potential therapeutic applications. While specific details about its molecular structure and properties may not be widely available, compounds like CH-5447240 are typically characterized by their unique functional groups, which influence their reactivity and biological activity. Such substances are often evaluated for their efficacy in targeting specific biological pathways or diseases. In the context of drug development, characteristics such as solubility, stability, and bioavailability are crucial for determining the compound's potential as a therapeutic agent. Additionally, safety profiles, including toxicity and side effects, are essential considerations during the research and development phases. As with many compounds in the pharmaceutical pipeline, ongoing studies and clinical trials will provide further insights into its characteristics and applications.

CH5447240 is a potent  Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist for Treatment of Hypoparathyroidism. CH5447240 exhibited a potent in vitro hPTHR1 agonist effect with EC20 of 3.0 nM and EC50 of 12 nM and showed excellent physicochemical properties, such as high solubility in fasted state simulated intestinal fluid and good metabolic stability in human liver microsomes.  mportantly,  CH5447240 showed 55% oral bioavailability, and a significantly elevated serum calcium level in hypocalcemic model rats.

CH5447240

(CH-5447240)

1253919-92-4: CH-5447240, also known by its CAS number 1253919-92-4, is a chemical compound that has garnered attention in pharmaceutical research, particularly in the context of its potential therapeutic applications. While specific details about its molecular structure and properties may not be widely available, compounds like CH-5447240 are typically characterized by their unique functional groups, which influence their reactivity and biological activity. Such substances are often evaluated for their efficacy in targeting specific biological pathways or diseases. In the context of drug development, characteristics such as solubility, stability, and bioavailability are crucial for determining the compound's potential as a therapeutic agent. Additionally, safety profiles, including toxicity and side effects, are essential considerations during the research and development phases. As with many compounds in the pharmaceutical pipeline, ongoing studies and clinical trials will provide further insights into its characteristics and applications.

CH5447240: potent hPTHR1 agonist, treats Hypoparathyroidism, EC50 12 nM, 55% oral bioavailability, raises rat serum calcium.

CAS 1253919-92-4

CH5447240 (CH-5447240)

CH5447240

Ref: TM-T25234